New Hope
NASDAQ:NRXP
NRX-101 has the potential to offer the first ray of hope to patients with suicidal depression, potentially transforming NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) into a biotech blockbuster, with sales of $1 billion - $2 billion annually!
While NRx continues to develop NRX-101, it has already accumulated data proving that its ketamine product (NRX-100) is superior to placebo in reducing symptoms of suicidality and depression. Positive trials, funded by the US govt and the French govt with nearly 1,000 patients. The company has already been awarded FDA Fast Track designation for ketamine and has created a daughter company, HOPE Therapuetics to start selling the ketamine product THIS MONTH.
NRx has stated in writing that current investors in NRx will also be given shares in HOPE Therapeutics, which is planned to go public over the summer.
This biotech company an irresistible proposition, not to be overlooked.
Suicide kills >50,000 Americans every year
Disproportionately affecting people with Bipolar Disorder
As we embark on this transformative journey, NRx Pharmaceuticals (NASDAQ: NRXP) extends a warm invitation to join us in pioneering innovative solutions to combat the profound challenges posed by mental health disorders. At the forefront of our mission lies a steadfast commitment to addressing the urgent and pressing issue of suicidal depression.
Central to our groundbreaking endeavors is NRX-100, an intravenous ketamine formulation poised to redefine the treatment landscape for acute suicidality and depression. With its potential to offer rapid relief and hope to those in desperate need, NRX-100 represents a beacon of light in the darkness of despair. NRX-100 starts sales this month and is expected to turn NRx Pharmaceuticals (through its HOPE subsidiary) into a revenue-generating company in 2024!
The shorts who have driven the price of NRx into the gutter want you to think that this is another hopeless biotech that will go bankrupt long before it generates revenue. UNFORTUNATELY THE SHORTS ARE MISTAKEN!
Furthermore, our robust pipeline includes NRX-101, a breakthrough therapy designated by the FDA for the treatment of suicidal treatment-resistant bipolar depression and chronic pain. Leveraging the power of D-Cycloserine (DCS) in combination with lurasidone, NRX-101 holds immense promise in providing much-needed relief to individuals grappling with these debilitating conditions
Beyond psychiatric disorders, NRx Pharmaceuticals is dedicated to addressing the complex challenges associated with chronic pain, post-traumatic stress disorder (PTSD) and complicated urinary tract infections (UTI) through the innovative potential of NRX-101.
As we continue to advance our pioneering research and clinical trials, we invite you to join us in our mission to transform the landscape of mental health therapeutics and beyond. Together, let us forge a path towards a brighter future, where innovative treatments offer hope and healing to individuals around the world. Join us in shaping the future of healthcare with NRx Pharmaceuticals.
NRx aims to provide state-of-the-art patient & reimbursement support for all of its patients and their clinics, ensuring access to insurance vulnerable populations”
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain.
NRx has recently announced plans to submit a New Drug Application for ketamine in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement.
NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
NRx brings hope:
Life-saving medicines
For people living with unmet medical needs.
We believe in a world where scientific advancement makes untreatable diseases treatable.
HOPE Therapeutics, an NRx Pharma daughter company, is developing NRX-100 (IV Ketamine) for treatment of Acute Suicidality and Depression.
Learn more about how we are bringing hope to 3.5 million lives in the United States.
"Subsequent to our announcement last week, we are in the process of completing a Memorandum of Understanding that may enable us to begin sales of IV ketamine to qualified clinics in partnership with a holder of a nationwide pharmacy license. Additionally, we will be updating investors with regard to our plans to add a digital therapeutic component to our ketamine offering that has potential to extend the clinical benefit to patients."
"We thank our investors for their support and look forward to updating the public on our progress towards building a lifesaving therapy."
"In a very difficult biotechnology capital market, we are pleased to benefit from the support of committed long-term investors, particularly in their willingness to purchase unregistered shares for the purpose of long-term appreciation. In the coming months, we expect to receive data from two important clinical trials, one in Suicidal Bipolar Depression and one in Chronic Pain, as well as advance our HTX-100 program in Suicidal Depression with the launch of Hope Therapeutics,"
Bipolar disorder is an illness that affects approximately 7 million individuals in the USA. It can cause notable changes in a person’s mood, energy and ability to think clearly.
People with bipolar disorder experience high and low moods—known as mania (highs) and depression (lows). These common, severe mood changes are different and generally much more pronounced than the mood changes most experience.
Patients with Bipolar Depression are 20-30x more likely to attempt suicide than the general population. Over the course of 5 years, 1 in 5 patients suffering from Bipolar Depression will attempt suicide. Estimates indicate that 11-20% of those with Bipolar Disorder succumb to suicide.
Chronic Pain is at the heart of the Opioid Crisis
Few new drugs are on the horizon
NRX-101 may offer hope
The current opioid crisis, fueled by a failure of non-opioid medication to achieve meaningful clinical relief, creates an acute need for nonaddictive, non-sedating pain medication.
New academic and pre-clinical research shows that NMDA receptors are active at each step of the pain pathway: From the focal point of our pain, through the peripheral nervous system, up our Spinal cord to the brain.
D-Cycloserine (DCS), an active ingredient of NRX-101, is a potent NMDA antagonist at high-enough doses. We are developing NRX-101 to treat chronic pain by modulating the NMDA receptor at every step of the pain pathway.
PTSD can happen to anyone. It is not a sign of weakness. A number of factors can increase the chance that someone will develop PTSD, many of which are not under that person’s control.
PTSD occurs after people go through, or witness, life-threatening events. These can be single, traumatic instances, or intense, long-lasting traumatic experiences. These include war and combat, sexual assault, disasters and mass violence.
Anyone can develop PTSD, and its not under a person’s control. PTSD is also more common after combat or sexual assault.
If you know five people with bipolar disorder, on average one will succumb to suicide. After centuries of mystery about the mechanism of bipolar disorder, major breakthroughs in unlocking the mystery began with Professor Daniel Javitt’s 1987 discovery that the NMDA receptor of the brain is the key to maintaining control over the rate at which thoughts are formed and the manner in which brain cells connect to one another.
Javitt’s work began with an attempt to explain the mechanism of drug-induced psychosis, a condition where people’s thoughts race out of control and hallucinations are common. Over the subsequent 25 years, it has become apparent that the NMDA receptor also has a major effect on depression and, particularly, thoughts of suicide. NRx is on a mission to bring hope to people who suffer from suicidal depression and PTSD through a new generation of NMDA-modulating medicines.
D-cycloserine, patented by Javitt as an antidepressant and antisuicidal drug, is approved worldwide as an anti-infective, primarily used for the treatment of tuberculosis. Although its anti-infective activity is based on its ability to disrupt bacterial cell walls, it also acts as an NMDA antagonist when used at high doses (> 500 mg). By targeting the NMDA receptor and modulating NMDA activity, D-cycloserine seems to foster a normal pace of thought generation. Multiple exploratory clinical studies have demonstrated that administration of D-cycloserine can trigger an antidepressant effect, as well as maintain a reduced level of suicidality.
Humankind is only at the dawn of understanding brain chemistry. The world’s most advanced computer lacks the creativity of a human brain. In part, that’s because electronic computers are completely binary in their logic circuits. Circuits are hard-wired to one another. Electrical connections are either on or off. The brain, however, is an analog computer in which both chemical and electrical signals modulate brain cells, which are constantly forming and breaking connections to one another.
Suicidal depression stands as a pervasive and urgent concern in our society, casting a shadow over the lives of millions worldwide. For those grappling with this debilitating condition, each day can feel like an insurmountable struggle, fraught with despair and hopelessness. Traditional treatment options often fall short, leaving many individuals trapped in a cycle of anguish with limited avenues for relief.
However, amidst the darkness, a beacon of hope emerges in the form of NRX-100 (IV Ketamine) from NRx Pharmaceuticals (Nasdaq: NRXP). This groundbreaking therapy offers a glimmer of light for those battling acute suicidal depression, providing a novel approach to intervention and potentially saving countless lives. With NRx Pharmaceuticals' innovative solutions and unwavering commitment to addressing mental health challenges, there is newfound optimism for a future where the grip of suicidal depression is loosened, and individuals find solace and healing.
In response to the pervasive problem of suicidal depression, NRx Pharmaceuticals (Nasdaq: NRXP) presents a groundbreaking solution: NRX-100 (IV Ketamine). This innovative therapy offers a ray of hope for individuals grappling with acute suicidal depression, providing a path towards healing and recovery.
NRX-100, developed by NRx Pharmaceuticals, represents a paradigm shift in the treatment landscape, offering a novel approach to addressing the profound challenges of suicidal depression. With its potential to provide rapid relief and alleviate symptoms, NRX-100 stands as a beacon of light in the darkness, offering renewed hope to those who have long struggled in silence.
Moreover, NRx Pharmaceuticals' dedication to advancing research and development in mental health extends beyond suicidal depression. With initiatives such as NRX-101 for chronic pain, D-Cycloserine (DCS) for PTSD, and NRX-101 for complicated UTI, the company is poised to revolutionize treatment across a spectrum of conditions, offering comprehensive solutions to complex challenges.
NRx is currently investigating our approach in FDA clinical trials. Results from our STABIL-B phase 2 study were presented at the American College of Neuropsychopharmacology in December 2018, and the FDA granted breakthrough therapy designation (BTD) to NRX-101 based on this study.
Results from NRx Pharma’s STABIL-B trial, a phase 2 study were presented at the American College of Neuropsychopharmacology in December 2018. The FDA granted breakthrough therapy designation (BTD) to NRX-101 based on this study.
A full, peer-reviewed report of the STABIL-B Trial is published in the International Journal of Bipolar Disorders and can be found here.
"We at NRx are honored that Lotus has focused its resources on helping us advance NRX-101 for the benefit of patients in the Asia Pacific region. As reported by the World Health Organization, suicidal depression is a significant public health crisis in Pacific rim countries, just as it is in the US,"
"We recently held very productive meetings at the JP Morgan conference in San Francisco; we share a mutual commitment to bringing a lifesaving treatment to patients who have been excluded from the clinical trials of all known antidepressants and whose only approved treatment today is electroshock therapy."
"We at NRx are delighted to partner with the thought leaders at Columbia University to help seek FDA approval for this extraordinary public health need. Until now, the only FDA-approved treatment for suicidal depression has been electroshock therapy (ECT). Recent literature suggests that ketamine may actually be superior to ECT in reducing suicidal ideation, while certainly having a more benign side effect profile,"
"Although ketamine is widely used off-label in the United States and is considered standard of care by some professionals, until it is labeled for treating depression and suicidality it will be widely accessible only to those patients able to pay out of pocket for their care and will continue to be subject to various warnings about off label use of a controlled substance."
At NRx Pharmaceuticals (Nasdaq: NRXP), we're not just tackling challenges; we're pioneering solutions in the realm of mental health. With our groundbreaking therapies, including NRX-100 (IV Ketamine) for acute suicidal depression and NRX-101 for chronic pain, PTSD, and complicated UTI, we're at the forefront of innovation in biopharmaceuticals.
Our focus on addressing the prevalent issue of suicidal depression with NRX-100 exemplifies our commitment to making a tangible impact on mental health. This therapy offers rapid relief, providing a lifeline to those in their darkest moments, while our ongoing research into NRX-101 promises advancements in the treatment of various CNS disorders.
Investors keen on tapping into transformative opportunities should have NRXP on their radar. With a diverse pipeline targeting critical unmet needs, NRx Pharmaceuticals offers a compelling investment opportunity. The recent "Strong Buy" rating on Nasdaq and a target price of $3.75, based on analysts' projections, underscore the market's confidence in our potential for growth and success.
Furthermore, as we advance pivotal Phase 3 trials for NRX-100 and continue to achieve milestones with NRX-101, the momentum is building for NRXP. Positive developments could trigger a fundamental breakout, offering investors the chance to capitalize on our trajectory towards becoming a leader in mental health therapeutics.
In summary, NRx Pharmaceuticals represents more than just a biotech company; we're agents of change in the fight against mental illness. With a robust pipeline, strong market indicators, and a dedication to innovation, NRXP is poised to deliver value to investors while making a profound difference in the lives of countless individuals worldwide.
PLEASE NOTE WELL: Axe Capital Partners LLC are not registered as an Investment Advisor in any jurisdiction whatsoever.
Stocks profiled on Axe Capital Partners LLC web site are for informational purposes only. Information on these pages contains forward – looking statements that involve risk and uncertainties. The purpose of these profiles is to make investors aware of these companies and should not in any way come across as a recommendation to buy or sell in these securities. Investing in stocks involves risk. You should consult a qualified financial advisor or broker before making any investment decisions. All profiles are based on information that is available to the public. Past performance of stocks profiled on this web site is not a guarantee as to future performance. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Axe Capital Partners LLC to be free from misstatements or errors.
We do not give price targets in any of our written or recorded material.
Please do your own research and make your own investment decisions. Always remember that Axe Capital Partners LLC is not an analyst and we do not employ or contract any analysts. Investing in securities such as the ones mentioned on our website, in email, or consulted for are for high-risk tolerant individuals only and not the general public.
Whether you are an experienced penny stocks investor or not, you should always consult with a licensed penny stock broker before buying or selling any securities that Axe Capital Partners LLC profiles, mentions, in email updates, consults for or interviews. If shares are restricted, Axe Capital Partners LLC may sell them when they are registered. If the penny stocks shares are freely transferable, Axe Capital Partners LLC intends to sell them. At no time will any Axe Capital Partners LLC employees or affiliates undertake any activity that could be regarded in any fashion as improper or illegal. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
Many of the companies communicated in our emails or website are developmental stage companies with little or no operating or trading history. The information contained in our alerts should be viewed as commercial advertisement and is not intended to be investment opinion. The report is not provided to any particular individual with a view toward their investment circumstances. The information contained in our alerts is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge to individuals who wish to receive them. Our advertisements and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiles based solely on information contained in our report. Individuals should assume that all information contained in the alerts about profiled companies is not trust worthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some of all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing. The profiles are a service of Axe Capital Partners LLC, a marketing and advertising firm that may have been compensated. All direct and third party compensation received will be disclosed within each individual alert in accordance with section 17(b) of the nineteen thirty three Securities Act. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
Axe Capital Partners LLC distributes its Electronic Content and provides other promotional services with the intention of helping the “featured company and or companies” to create public awareness of their current business and future objectives, as well as to aid in the development of a liquid trading market for the “featured company’s” securities, although there is no intent to make a market or facilitate, in any manner, the purchase and sale of the “featured company and or companies” securities. Electronic Content refers to all Electronic Material distributed and created, and/or edited by Axe Capital Partners LLC and includes, but is not limited to Emails, Newsletters, any Social Media content such as Facebook and Twitter, Blog Postings, Video Content, Corporate Profiles, Corporate Videos, Analyst Reports, PowerPoint Presentations, CEO Video Interviews, Press releases, Banners, Images, Google Advertising, Microsoft Ad center Advertising, and/or web based discussion board postings of any kind.
Although there is no guarantee that a liquid market will develop in the “featured company’s” securities, in the event that an active market does develop, investors should be aware that existing shareholders (controlling, or non-controlling) will be motivated to sell their shares potentially creating an oversupply scenario, under which the price of the shares is likely to experience sudden declines. At the same time, if the existing shareholder base holds shares tightly, and an active trading market develops, this may result in sudden increases in the price of the stock due to a potential undersupply scenario. In any case, there can be no guarantee that the price of the stock will reflect the fundamental value of the “featured company and or companies”. Axe Capital Partners LLC disclaims all knowledge of the “featured company and/or companies” shareholder base, capacity for liquidity, or other means or methods of enhancing public awareness.
Forward Looking Statements
All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell penny stocks securities of the penny stocks companies profiled herein and any decision to invest in any such penny stocks company or other financial decisions should not be made based upon the information provide herein. Instead Axe Capital Partners LLC strongly urges you to conduct a complete due diligence of the respective penny stocks companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Axe Capital Partners LLC does not offer such advice or analysis, and Axe Capital Partners LLC urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth penny stocks securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
Axe Capital Partners LLC may feature or profile a company periodically (usually for life of contract) and may remove that profile at it’s own discretion. Profiles and disclosures for those profiles may or may not remain visible on Axe Capital Partners LLC website.
Axe Capital Partners LLC website may contain links to related websites including, but not limited to, stock charts, stock quotes, SEC data, NASD data, etc. We are not responsible for the content of or the privacy practices used by these sites. We encourage our readers to review all public filings by companies at the SEC’s EDGAR page located at SEC.gov. The Axe Capital Partners LLC has published information on how to invest carefully at NASD.com.
PLEASE READ CAREFULLY - Axe Capital Partners LLC is engaged in the business of marketing and advertising companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Axe Capital Partners LLC sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Axe Capital Partners LLC or an offer or solicitation to buy or sell any security. Neither the owner of Axe Capital Partners LLC nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters . Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk.
Notice of Stock Price Movements and Volatility Viewers of this newsletter should understand that trading activity and stock prices in many if not all cases tend to increase during the advertisement campaigns of the profiled companies and in many if not all cases tend to decrease thereafter. This tends to create above average volatility and price movements in the profiled company during the advertisement campaign that viewers should take into consideration at all times. Campaigns vary in length, and many are for short periods of time, typically less than a week. Some of the content in this release contains forward-looking information within the meaning of Section 27 A of the Securities Act of 1 993 and Section 21 E of the Securities Exchange Act of 1 934 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1 995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company’s actual results of operation. A company’s actual performance could greatly differ from those described in any forward looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company’s products; the company’s ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, a company’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable.
Axe Capital Partners LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Axe Capital Partners LLC Network has no obligation to update any of the information provided. Axe Capital Partners LLC, its owners, officers, directors, contractors and employees are not responsible for errors and omissions.
From time to time certain content in our releases or website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our releases and website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled in our release or on our website may not have approved certain or any statements within the website. Axe Capital Partners LLC encourages viewers to supplement the information obtained from this release and our website with independent research and other professional advice. The content in this release is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data.
This release may provide hyperlinks to third party websites or access to third party content. Axe Capital Partners LLC its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Axe Capital Partners LLC control, endorse, or guarantee any content found in such sites. By accessing, viewing, or using the website or communications originating from this release, you agree that Axe Capital Partners LLC its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Axe Capital Partners LLC, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
Axe Capital Partners LLC uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. You agree to hold Axe Capital Partners LLC its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur arising out of the use of our website or the information in our press releases, profiles and opinions. You agree that use of our website is at your sole risk. Axe Capital Partners LLC disclaims all warranties of any kind, express or implied. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the SEC. The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or then FINRA at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/investors/index.htm.
(Last updated: )